BioScrip, Inc. Reports 2010 First Quarter Results

ELMSFORD, N.Y.--(BUSINESS WIRE)-- BioScrip, Inc. (Nasdaq: BIOS) today announced a first quarter net loss of $7.2 million, or $0.18 per share on revenues of $335.1 million. These results compare to net income of $3.3 million, or $0.08 per share, on revenues of $325.7 million for the first quarter of 2009. The net loss includes one-time transaction expenses of $7.3 million ($5.5 million, net of taxes) related to the acquisition of Critical Homecare Solutions (“CHS”) and additional bad debt expense in connection with the Competitive Acquisition Program (“CAP”), which was terminated in 2008, of $1.5 million ($1.1 million, net of taxes). First quarter 2010 Adjusted EBITDA was $2.7 million compared to $6.2 million for the same period a year ago.

“We successfully closed the acquisition of CHS on March 25, 2010 and are pleased with the progress we have made to integrate them into our operations. We are on target to achieve our planned cost synergies and have identified additional cost of goods savings. Furthermore, we are seeing tangible results from our cross-selling efforts and continue to believe that the combined platform positions BioScrip to be a leading national, specialty pharmacy provider," stated Richard H. Friedman, BioScrip’s Chairman and Chief Executive Officer. “While our first quarter results were impacted by several seasonal and timing-related items, including the delayed implementation of new business from January to March, and the acceleration of certain operating expenses in the quarter, we ended March at our expected revenue levels and have similar momentum going into the second quarter.”

Results of Operations

Revenue for the first quarter of 2010 totaled $335.1 million compared to $325.7 million for the same period a year ago, an increase of 2.9%. Excluding the impact of the terminated United Health Group (“UHG”) organ transplant and HIV/AIDS programs, first quarter 2010 revenues grew 8.6% over the comparable period in 2009. The increase was due primarily to increased specialty pharmacy revenues and includes approximately $5 million of revenues from CHS representing four billing days in the quarter. Specialty revenues increased by approximately $23.0 million, or 22%, in March 2010 compared to the prior two months average. This increase is a result of new business and a return to normalized utilization levels resulting from post year-end seasonality.

Gross profit for the first quarter of 2010 was $38.9 million compared to $36.0 million for the first quarter of 2009. Gross margin for the first quarter 2010 was 11.6%, compared to 11.0% for the same period of 2009. The increase was a result of the inclusion of CHS and new business, which more than offset the unfavorable impact of the competitive market conditions in the traditional pharmacy services and the previously disclosed AWP class action litigation settlement.

The first quarter 2010 operating loss was $6.3 million compared to an operating profit of $4.3 million for the first quarter of 2009. The operating loss in the first quarter of 2010 includes $5.0 million of CHS transaction expenses and a $1.5 million charge related to CAP. Reported expenses include $1.2 million of accelerated employee benefits, increased temporary staffing and other non-recurring expenses.

Interest expense in the first quarter of 2010 was $3.2 million, which includes a $2.3 million fee from the financing of the CHS acquisition and $0.5 million interest expense related to the Company’s new capital structure. This compares to $0.6 million in the same period of 2009.


As of March 31, 2010, the Company had $37.2 million of cash and cash equivalents. In addition, the revolving credit facility remains undrawn.

Financial Guidance

The Company reaffirms full-year 2010 guidance of approximately $1.67 to $1.73 billion in revenue and adjusted EBITDA of $67.0 to $71.0 million.

Conference Call

BioScrip will host a conference call to discuss its first quarter 2010 financial results on Friday April 30, at 8:30 a.m. Eastern Time. Interested parties may participate in the conference call by dialing 800-926-7510 (US), or 212-231-2903 (International), 5-10 minutes prior to the start of the call. A replay of the conference call will be available from 12:00 p.m. Eastern Time on Friday, April 30, through 12:00 p.m. Eastern Time on May 21, by dialing 800-633-8284 (US), or 402-977-9140 (International), and entering reservation number 21467687. An audio web cast and archive of the conference call will also be available under the investor relations section of the BioScrip website at

About BioScrip, Inc.

BioScrip, Inc. ( (Nasdaq: BIOS) is a specialty pharmaceutical healthcare organization that partners with patients, physicians, healthcare payers and pharmaceutical manufacturers to provide access to medications and management solutions to optimize outcomes for chronic and other complex health care conditions.

Forward Looking Statements-Safe Harbor

This press release may contain statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company, Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Important factors that could cause such differences are described in the Company's periodic filings with the Securities and Exchange Commission.

Earnings before interest, taxes, depreciation, amortization, and option expense ("EBITDAO") is a non-GAAP financial measure as defined under U.S. Securities and Exchange Commission Regulation G. As required by Regulation G, BioScrip has provided on Schedule 3 a reconciliation of this measure to the most comparable GAAP financial measure. The non-GAAP measure presented provides important insight into the ongoing operations and a meaningful benchmark to evidence the Company's continuing profitability trend.

(in thousands, except for share amounts)
  March 31,   December 31,
2010 2009
ASSETS (unaudited)
Current assets
Cash and cash equivalents $ 37,245 $ -

Receivables, less allowance for doubtful accounts of $13,113 and $11,504 at March 31, 2010 and December 31, 2009, respectively

179,212 151,113
Inventory 60,406 51,256
Deferred taxes 23,218 12,913
Prepaid expenses and other current assets   14,339     3,999  
Total current assets   314,420     219,281  
Property and equipment, net 22,514 15,454
Deferred taxes 13,848 26,793
Goodwill 309,771 24,498
Intangible assets, net 44,724 -
Deferred financing costs 11,082 -
Other non-current assets   4,204     1,194  
Total assets $ 720,563   $ 287,220  
Current liabilities
Line of credit $ - $ 30,389
Current portion of long-term debt 2,628 -
Accounts payable 81,648 74,535
Notes payable 2,250 -
Claims payable 2,070 4,068
Amounts due to plan sponsors 14,194 4,938
Deferred revenue 3,657 -
Accrued expenses and other current liabilities   27,944     14,273  
Total current liabilities   134,391     128,203  
Long-term debt, net of current portion 322,690 -
Income taxes payable 5,980 2,437
Other non-current liabilities   911     787  
Total liabilities   463,972     131,427  
Stockholders' equity
Common stock, $.0001 par value; 75,000,000 shares authorized; shares issued: 55,980,327 and 42,766,478, respectively; shares outstanding; 53,014,245 and 39,675,865, respectively
6 4
Treasury stock, shares at cost: 2,652,917 and 2,647,613, respectively (10,478 ) (10,367 )
Additional paid-in capital 362,753 254,677
Accumulated deficit   (95,690 )   (88,521 )
Total stockholders' equity   256,591     155,793  
Total liabilities and stockholders' equity $ 720,563   $ 287,220  
Schedule 2
(in thousands, except per share amounts)
  Three Months Ended
March 31,
2010   2009
Revenue $ 335,068 $ 325,749
Cost of revenue   296,150     289,759  
Gross profit 38,918 35,990
% of Revenue 11.6 % 11.0 %
Operating expenses
Selling, general and administrative expenses 36,354 30,327
Bad debt expense 3,650 1,380
Acquisition and integration expenses 5,040 -
Amortization of intangibles   176     -  
Total operating expense 45,220 31,707
% of Revenue 13.5 % 9.7 %
(Loss) income from operations (6,302 ) 4,283
Interest expense, net   3,169     594  
(Loss) income before income taxes (9,471 ) 3,689
Tax (benefit) provision   (2,302 )   404  
Net (loss) income $ (7,169 ) $ 3,285  
Basic weighted average shares   40,825     38,709  
Diluted weighted average shares   40,825     38,787  


Basic net (loss) income per share

$ (0.18 ) $ 0.08

Diluted net (loss) income per share

$ (0.18 ) $ 0.08
Schedule 3
Reconciliation between GAAP and Non-GAAP Measures
(in thousands, except per share amounts)
  Three Months
March 31,
2010   2009
Net (Loss) income $ (7,169 ) $ 3,285
Addback items:
Depreciation and amortization 1,660 1,111
Interest expense, net 3,169 594
Taxes (2,302 ) 404
Stock-based compensation expense   804     776

Earnings before interest, taxes, depreciation, amortization and share-based compensation expense (EBITDAO)

$ (3,838 ) $ 6,170
Adjusted EBITDA $ (3,838 ) $ 6,170
Addback unusual or infrequent items:
Acquisition and integration related costs 5,040 -
Bad debt expense related to contract termination   1,483     -
Adjusted EBITDA $ 2,685   $ 6,170


BioScrip, Inc.
Stanley G. Rosenbaum, 952-979-3768
Executive Vice President and Chief Financial Officer
[email protected]
In-Site Communications
Bill Bunting, 212-759-3929
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Pharmaceutical  Other Health  General Health